JP2025500944A5 - - Google Patents
Info
- Publication number
- JP2025500944A5 JP2025500944A5 JP2024537033A JP2024537033A JP2025500944A5 JP 2025500944 A5 JP2025500944 A5 JP 2025500944A5 JP 2024537033 A JP2024537033 A JP 2024537033A JP 2024537033 A JP2024537033 A JP 2024537033A JP 2025500944 A5 JP2025500944 A5 JP 2025500944A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- sequence
- region
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163291910P | 2021-12-20 | 2021-12-20 | |
| US63/291,910 | 2021-12-20 | ||
| PCT/US2022/082021 WO2023122588A2 (en) | 2021-12-20 | 2022-12-20 | Egfr-cmet–targeted compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025500944A JP2025500944A (ja) | 2025-01-15 |
| JP2025500944A5 true JP2025500944A5 (enExample) | 2025-12-24 |
Family
ID=86903719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024537033A Pending JP2025500944A (ja) | 2021-12-20 | 2022-12-20 | ＥＧＦＲ－ｃＭＥＴ標的化合物及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20250121104A1 (enExample) |
| EP (1) | EP4452954A2 (enExample) |
| JP (1) | JP2025500944A (enExample) |
| KR (1) | KR20240125970A (enExample) |
| CN (1) | CN118765273A (enExample) |
| AR (1) | AR128052A1 (enExample) |
| AU (1) | AU2022419564A1 (enExample) |
| CA (1) | CA3244030A1 (enExample) |
| CL (1) | CL2024001832A1 (enExample) |
| CO (1) | CO2024008733A2 (enExample) |
| CR (1) | CR20240254A (enExample) |
| IL (1) | IL313333A (enExample) |
| MX (1) | MX2024007596A (enExample) |
| TW (1) | TW202333799A (enExample) |
| WO (1) | WO2023122588A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3265502A1 (en) * | 2022-08-22 | 2024-02-29 | Abdera Therapeutics Inc. | DOTA ANTIBODY CONJUGATES VHH |
| EP4763865A1 (en) * | 2023-08-14 | 2026-06-24 | Minghui Pharmaceutical (Hangzhou) Limited | Anti-c-met nanobody and use thereof |
| WO2025148868A1 (zh) | 2024-01-08 | 2025-07-17 | 泰励生物科技（上海）有限公司 | 一种抗体偶联药物及其用途 |
| CN118085101A (zh) * | 2024-03-01 | 2024-05-28 | 烟台蓝纳成生物技术有限公司 | 一种二价双特异性抗体、抗体偶联核素药物及其应用 |
| WO2025195500A1 (zh) * | 2024-03-22 | 2025-09-25 | 康源博创生物科技(北京)有限公司 | 一种多肽及其用于构建包含共同轻链的双特异性抗体中的应用 |
| WO2026149557A1 (zh) * | 2025-01-10 | 2026-07-16 | 正大天晴药业集团股份有限公司 | 新型亲水性连接体及其药物连接体、蛋白质偶联药物、药物组合物和用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3823988A1 (en) * | 2018-07-19 | 2021-05-26 | Eli Lilly and Company | Bispecific antibodies targeting immune checkpoints |
| WO2021133036A1 (ko) * | 2019-12-23 | 2021-07-01 | 주식회사 엘지화학 | 항-lilrb1 항체 및 그의 용도 |
| KR20220157464A (ko) * | 2020-03-23 | 2022-11-29 | 퓨전 파마슈티칼즈 인크. | Fgfr3-표적화된 방사선면역접합체 및 그의 용도 |
| WO2021207086A1 (en) * | 2020-04-06 | 2021-10-14 | Fusion Pharmaceuticals Inc. | Tem-1-targeted radioimmunoconjugates and uses thereof |
-
2022
- 2022-12-20 JP JP2024537033A patent/JP2025500944A/ja active Pending
- 2022-12-20 AU AU2022419564A patent/AU2022419564A1/en active Pending
- 2022-12-20 WO PCT/US2022/082021 patent/WO2023122588A2/en not_active Ceased
- 2022-12-20 IL IL313333A patent/IL313333A/en unknown
- 2022-12-20 CN CN202280092041.0A patent/CN118765273A/zh active Pending
- 2022-12-20 EP EP22912656.0A patent/EP4452954A2/en active Pending
- 2022-12-20 US US18/721,647 patent/US20250121104A1/en active Pending
- 2022-12-20 CA CA3244030A patent/CA3244030A1/en active Pending
- 2022-12-20 CR CR20240254A patent/CR20240254A/es unknown
- 2022-12-20 MX MX2024007596A patent/MX2024007596A/es unknown
- 2022-12-20 TW TW111149059A patent/TW202333799A/zh unknown
- 2022-12-20 KR KR1020247024103A patent/KR20240125970A/ko active Pending
- 2022-12-21 AR ARP220103534A patent/AR128052A1/es unknown
-
2024
- 2024-06-18 CL CL2024001832A patent/CL2024001832A1/es unknown
- 2024-06-28 CO CONC2024/0008733A patent/CO2024008733A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019139434A (ru) | Моноклональные антитела против igf-1r и их применение | |
| RU2019139432A (ru) | Фармакокинетическая оптимизация бифункциональных хелатов и их применение | |
| JP2020518673A5 (enExample) | ||
| JP2014507400A (ja) | Ｎｏｔａによって錯体化されたアルミニウム−［１８ｆ］フッ化物で標識されたｈｅｒ２結合ペプチド | |
| JP2024503924A5 (enExample) | ||
| JP2023076712A (ja) | 放射標識生体分子およびその使用 | |
| US20250121104A1 (en) | Egfr-cmet-targeted compounds and uses thereof | |
| KR20220083768A (ko) | 방사성 금속 표지 항체의 제조 방법 | |
| JP2024523344A (ja) | 生物製剤を複数のキレーターと組み合わせるための方法及び材料 | |
| WO2023033022A1 (ja) | 脱グリコシル化抗体の放射性複合体、及び、放射性医薬 | |
| CN120129534A (zh) | 放射性药物组合物 | |
| TW202304532A (zh) | 治療癌症之方法 | |
| TH2401004071A (th) | สารประกอบที่มุ่งเป้า EGFR-cMET และการใช้สิ่งดังกล่าว | |
| CN118317796A (zh) | EGFRvIII靶向化合物及其用途 | |
| TW202144008A (zh) | 標靶fgfr3之放射免疫結合物及其用途 | |
| US20240350682A1 (en) | Steap2-targeted compounds and use thereof | |
| WO2022211051A1 (ja) | 抗ｅｇｆｒ抗体の放射性複合体、及び、放射性医薬 | |
| AU2023468278A1 (en) | Novel therapeutic targets | |
| HK40084697A (en) | Fgfr3-targeted radioimmunoconjugates and uses thereof | |
| WO2022224980A1 (ja) | 抗ｃｄ２０抗体の放射性複合体、及び、放射性医薬 | |
| WO2023157822A1 (ja) | 抗ｖｅｇｆ抗体の放射性複合体、及び、放射性医薬 | |
| TW202508645A (zh) | 放射性藥物用於癌症治療之用途 |